Status
Conditions
Treatments
About
This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male 50-80 years of age Eligible for interstitial brachytherapy implants
Exclusion criteria
10 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal